News

Life Sciences

Proteostasis Raises $74 Million in Follow-on Offering After Positive Cystic Fibrosis Data

Edward Kim | Equities.com |

Positive preliminary results from all cohorts of combination Phase 1 study (Image: Proteostasis Therapeutics)


Stoke Therapeutics Raises $90 Million Series B for Therapies to Restore Gene Expression

Edward Kim | Equities.com |

Antisense oligonucleotide therapies to increase gene expression for the treatment of severe genetic diseases. Lead candidate in Dravet Syndrome (Image: Stoke Therapeutics).


Gamida Cell's $50 Million IPO Expected This Week for Blood Cancers

Edward Kim | Equities.com |

Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)


Clovis Oncology Shows Positive Initial Phase 2 Data in Prostate Cancer

Edward Kim | Equities.com |

44% confirmed objective response rate in metastatic castration resistant prostate cancer. Rubraca (rucaparib) is FDA approved as maintenance treatment for ovarian cancer. (Image: Clovis Oncology)


LogicBio's $75 Million IPO Expected This Week for Rare Disease Gene Therapy

Edward Kim | Equities.com |

Genome editing technology, Initially targeting rare liver disorders in pediatric patients (Image: LogicBio).


CytoBioscience: Microcap Play in the $55 Billion Life Science Instrumentation Market

Edward Kim | Equities.com |

Market expected to grow to over $75 billion by 2022 (Image: CiPA Initiative)


resTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections

Edward Kim | Equities.com |

RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)


AcelRx Gets FDA Advisory Committee Recommendation for Acute Pain Therapy

Edward Kim | Equities.com |

Anesthetic & Analgesic Drug Products Advisory Committee voted 10-3 in recommending approval of Dsuvia (sublingual sufentanil) for acute pain in medically supervised settings (Image: AcelRx).


PhaseBio's $65 Million IPO Expected Next Week for Orphan Cardiopulmonary Diseases

Edward Kim | Equities.com |

Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)


TG Therapeutics Shows Positive Final Phase 2 Data in Relapsing Multiple Sclerosis

Edward Kim | Equities.com |

Data presented at ECTRIMS, the world's largest MS conference


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.